REL Gene: REL Proto-Oncogene, NF-kB Subunit
Comprehensive genomic and functional analysis of the REL gene, a key transcription factor in immune regulation and oncogenesis.
Gene Information Card
| Symbol | REL |
|---|---|
| Full Name | REL proto-oncogene, NF-kB subunit |
| Gene Type | protein-coding |
| Chromosomal Location | 2p16.1 |
| NCBI Gene ID | 5966 ncbi.nlm.nih.gov/gene/5966 |
| Ensembl ID | ENSG00000162924 |
| UniProt ID | Q04864 |
| OMIM ID | 164910 |
| HGNC ID | 9955 |
| Aliases | c-Rel, NF-kB p65 subunit, RELA-like |
Description
The REL gene encodes the c-Rel protein, a member of the NF-kB family of transcription factors. c-Rel forms homodimers or heterodimers with other NF-kB subunits (e.g., p50, p65) and regulates the expression of genes involved in immune response, inflammation, cell survival, and proliferation. REL is classified as a proto-oncogene due to its frequent amplification and overexpression in B-cell lymphomas and other cancers.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Diffuse Large B-cell Lymphoma | REL amplification leads to increased NF-kB signaling, promoting cell survival and proliferation. | Amplification observed in ~20% of DLBCL cases (COSMIC, ClinVar). |
| Hodgkin Lymphoma | REL amplification and overexpression contribute to constitutive NF-kB activation in Hodgkin/Reed-Sternberg cells. | Frequent gain/amplification reported (NCBI, OMIM). |
| Primary Mediastinal B-cell Lymphoma | REL amplification is a hallmark genomic alteration driving NF-kB pathway activation. | Recurrent amplification at 2p16.1 (COSMIC, ClinVar). |
| Follicular Lymphoma | REL amplification may occur as a secondary event, enhancing NF-kB signaling. | Amplification reported in a subset of cases (NCBI). |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Lymph node | 12.5 | High |
| Spleen | 10.8 | High |
| Bone marrow | 8.2 | Medium |
| Lung | 4.1 | Low |
| Brain | 1.3 | Not detected |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| Raji (Burkitt lymphoma) | 15.2 | High expression; NF-kB active |
| Jurkat (T-cell leukemia) | 9.7 | Moderate expression |
| HEK293 (embryonic kidney) | 3.5 | Low expression |
| HeLa (cervical carcinoma) | 5.8 | Medium expression |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| REL amplification | Copy number gain | ~20% in DLBCL | Increased NF-kB activity |
| REL p.Gly307Arg | Missense | <1% in lymphoid malignancies | Unknown functional effect |
| REL p.Arg335* | Nonsense | Rare | Loss of function (truncation) |
Mutation functional classification
Loss of Function (LOF)
Rare nonsense mutations (e.g., p.Arg335*) lead to truncated protein and reduced NF-kB signaling.
Gain of Function (GOF)
Gene amplification and overexpression result in constitutive NF-kB activation, promoting oncogenesis.
Dominant Negative (DN)
Not well documented; some missense variants may interfere with dimerization but evidence is limited.
View complete mutation data:
Gene Ontology (GO)
Pathways
• NF-kB signaling pathway (KEGG hsa04064)
• Toll-like receptor signaling pathway (KEGG hsa04620)
• B cell receptor signaling pathway (KEGG hsa04662)
• TNF signaling pathway (KEGG hsa04668)
Protein Summary
The c-Rel protein (UniProt Q04864) is a 619-amino acid transcription factor containing a conserved N-terminal Rel homology domain (RHD) responsible for DNA binding and dimerization, and a C-terminal transactivation domain. It shuttles between cytoplasm and nucleus; upon activation, it translocates to the nucleus to regulate target genes. c-Rel is critical for B-cell and T-cell function, and its dysregulation is a hallmark of several lymphoid malignancies.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| RELA Knockout HEK293 Cell Line | EDJ-KQ588 | Human | 5970 | Details Get a Quote |
| RELB Knockout HEK293 Cell Line | EDJ-KQ589 | Human | 5971 | Details Get a Quote |
| RELN Knockout HEK293 Cell Line | EDJ-KQ863 | Human | 5649 | Details Get a Quote |
| CRELD2 Knockout HEK293 Cell Line | EDJ-KQ1086 | Human | 79174 | Details Get a Quote |
| REL Knockout HEK293 Cell Line | EDJ-KQ1253 | Human | 5966 | Details Get a Quote |
| PRELP Knockout HEK293 Cell Line | EDJ-KQ5525 | Human | 5549 | Details Get a Quote |
| AREL1 Knockout HEK293 Cell Line | EDJ-KQ6793 | Human | 9870 | Details Get a Quote |
| PRELID3A Knockout HEK293 Cell Line | EDJ-KQ7117 | Human | 10650 | Details Get a Quote |
| KIRREL2 Knockout HEK293 Cell Line | EDJ-KQ9962 | Human | 84063 | Details Get a Quote |
| KIRREL3 Knockout HEK293 Cell Line | EDJ-KQ10134 | Human | 84623 | Details Get a Quote |
| RELT Knockout HEK293 Cell Line | EDJ-KQ10284 | Human | 84957 | Details Get a Quote |
| PRELID2 Knockout HEK293 Cell Line | EDJ-KQ11537 | Human | 153768 | Details Get a Quote |
| IL17REL Knockout HEK293 Cell Line | EDJ-KQ11600 | Human | 400935 | Details Get a Quote |
| CRELD1 Knockout HEK293 Cell Line | EDJ-KQ13002 | Human | 78987 | Details Get a Quote |
| KIRREL1 Knockout HEK293 Cell Line | EDJ-KQ13211 | Human | 55243 | Details Get a Quote |
Displaying Records 1 To 15 Of 72 Records
- 1
- 2
- Next Page »